

Title (en)
TYROSIN-DERIVATE AS ALPHA-V-INTEGRIN INHIBITORS

Title (de)
TYROSIN-DERIVATE ALS ALPHA-V-INTEGRIN-INHIBITOREN

Title (fr)
DERIVES DE TYROSINE UTILISES COMME INHIBITEURS D'ALPHA-V-INTEGRINE

Publication
EP 0879227 A1 19981125 (DE)

Application
EP 96944578 A 19961216

Priority
• DE 19548709 A 19951223
• EP 9605646 W 19961216

Abstract (en)
[origin: DE19548709A1] Disclosed are compounds of formula (I) in which X represents alkylene with 1-6 C atoms or 1,4-piperidyl; Y is absent or represents O, CONH or -CC-; R<1> represents H, CN, N3, NH2, H2N-C(=NH) or H2N-(C=NH)-NH (the primary amino groups can also be provided with conventional amino protective groups); R<2>, R<3> each independently of one another represent H, A, A-SO2-, Ar-SO2, campher-10-SO2-, COOA or a conventional amino protective group; A, R<4> each independently of one another represent H or alkyl with 1-10 C atoms; and Ar represents phenyl or benzyl which is unsubstituted or single-substituted with CH3. Also disclosed are the physiologically tolerable salts of these compounds. The compounds and salts thereof can be used as alpha v-integrin inhibitors, in particular for treating tumours, osteoporoses, osteolytic disorders and for suppressing angiogenesis.

IPC 1-7
C07C 311/06; **A61K 31/195**; **C07C 247/04**; **C07C 257/14**; **C07C 271/22**; **C07C 279/08**; **C07C 311/10**; **C07C 311/13**; **C07C 311/14**; **C07C 311/19**; **C07D 211/62**

IPC 8 full level
A61K 31/00 (2006.01); **A61K 31/195** (2006.01); **A61K 31/445** (2006.01); **A61K 31/4465** (2006.01); **A61P 5/24** (2006.01); **A61P 19/00** (2006.01); **A61P 19/10** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07C 271/22** (2006.01); **C07C 271/28** (2006.01); **C07D 211/46** (2006.01); **C07C 279/08** (2006.01); **C07C 311/06** (2006.01); **C07C 311/10** (2006.01); **C07C 311/13** (2006.01); **C07C 311/14** (2006.01); **C07C 311/19** (2006.01); **C07D 211/62** (2006.01)

CPC (source: EP KR)
A61K 31/195 (2013.01 - KR); **A61P 5/24** (2018.01 - EP); **A61P 19/00** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07C 247/04** (2013.01 - KR); **C07C 271/28** (2013.01 - EP); **C07C 279/08** (2013.01 - EP); **C07C 311/06** (2013.01 - EP KR); **C07C 311/14** (2013.01 - EP); **C07C 311/19** (2013.01 - EP); **C07D 211/62** (2013.01 - EP KR); **Y02P 20/55** (2015.11 - EP)

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)
WO 9723451 A1 19970703; AU 1301697 A 19970717; BR 9612201 A 19990713; CA 2241149 A1 19970703; CZ 195198 A3 19981111; DE 19548709 A1 19970703; EP 0879227 A1 19981125; HU P9903716 A2 20000328; JP 2000502664 A 20000307; KR 19990076676 A 19991015; MX 9804971 A 19980930; NO 982907 D0 19980622; NO 982907 L 19980622; PL 327185 A1 19981123; SK 78398 A3 19981104; ZA 9610725 B 19970626

DOCDB simple family (application)
EP 9605646 W 19961216; AU 1301697 A 19961216; BR 9612201 A 19961216; CA 2241149 A 19961216; CZ 195198 A 19961216; DE 19548709 A 19951223; EP 96944578 A 19961216; HU P9903716 A 19961216; JP 52328297 A 19961216; KR 19980704788 A 19980622; MX 9804971 A 19980619; NO 982907 A 19980622; PL 32718596 A 19961216; SK 78398 A 19961216; ZA 9610725 A 19961219